Were encouraging you to reach out to our team, which will carefully review your case and see if its fit for financial compensation
Novo said last week that CagriSema was "well-tolerated" and that the most common adverse effects were gastrointestinal, but they were "mild to moderate and diminished over time." "Investors are looking for treatment options that are best in class and will secure Novo's place in the obesity drug market," Soren Lontoft, pharma equity analyst at Sydbank, told CNBC over the phone Tuesday
The transition is typically gradual rather than sudden because the medication has a seven-day half-life, giving your appetite hormones time to readjust over four to five weeks
For clinics, this is a prime opportunity to capture this market through more efficient and convenient non-surgical in-office solutions like Sofwave
Contact Optalert to explore how we can work together to revolutionise the field of road safety.
Nausea is the most common early sign